{"text_format":"3","workbook":"xlsb","n_sheets":5,"sheets":["Cover","CET","Scenarios","Calculations","GDPCapita"],"not_rendered":{"charts":1,"images":4,"macros":1,"defined_names":9},"read":"bin_skipped_in_rows","date_system":"1900","formulas":"cached_only","passed_over":{"ids":[37,38,1024],"n":291}}

{"sheet":"Cover","index":0,"n_rows":19,"n_cols":17,"rows_kept":19,"merged":[[5,1,7,14],[9,1,11,14],[13,1,22,14]],"flags":["formulas_cached_only"]}
[null,"CET Calculator"]
[]
[]
[]
[null,"Introduction"]
[null,"Cost-effectiveness thresholds (CETs) are used to assess whether an intervention is worthwhile and should reflect health opportunity cost. By comparing the ICER with the CET, we can estimate if the intervention is cost effective."]
[]
[]
[null,"Aim"]
[null,"To identify the existence and magnitude of incremental cost-effectiveness thresholds and describe its characteristics to help stakeholders implement a suitable national cost-effectiveness threshold."]
[]
[]
[null,"Cost-effectiveness thresholds (CETs) Calculations"]
[null,"The cost-effectiveness threshold will dependent on various criteria: \n\n1) Relative health gain of the intervention (Incremental relative QALY gain)\n2) Proportional short fall\n3) Orphan drug\n\nTo calculate the CET, first determine the Incremental Relative QALYs Gains (IRQG) as shown in the provided equation. Use the IRQG value to find the corresponding multiplier from the given table. Multiply the IRQG multiplier by the Rare disease factor, the baseline threshold, and the proportional shortfall value.\n"]
[]
[]
[]
[]
[{"$nulls":16},"*The IRQG should be calculated based on the undiscounted QALYs"]

{"sheet":"CET","index":1,"n_rows":26,"n_cols":12,"rows_kept":26,"merged":[[4,1,5,4],[4,6,4,12],[5,6,5,10],[5,11,5,12],[6,1,7,2],[6,3,7,4],[7,6,8,10],[7,11,8,12],[8,1,8,2],[8,3,8,4],[9,6,9,10],[9,11,9,12],[10,1,10,2],[10,3,10,4],[11,6,11,12],[12,1,12,2],[12,3,12,4],[12,6,12,12],[14,2,15,2],[14,3,15,4],[15,11,16,12],[16,1,17,1],[16,2,17,2],[16,3,17,4],[17,11,18,12],[18,1,19,1],[18,2,19,2],[18,3,19,4],[19,11,20,12],[21,1,21,4],[21,11,22,12],[22,1,22,2],[22,3,22,4],[23,1,23,2],[23,3,23,4],[23,11,24,12],[25,11,26,12]],"flags":["formulas_cached_only"]}
[null,"CET Calculator"]
[]
[]
[]
[null,"Inputs",{"$nulls":4},"Severity of the Disease"]
[{"$nulls":6},"Proportional/Relative Shortfall",{"$nulls":4},{"v":0.11764705882352941,"d":"0.1176"}]
[null,"Country",null,"UAE"]
[{"$nulls":6},"Incremental Relative QALYs Gained (IRQG)",{"$nulls":4},"Multiplier"]
[null,"GDP per capita (2023)",null,"52,976.8"]
[null,"Source: World Bank Open Data.",{"$nulls":4},0.25,{"$nulls":4},{"v":4.1911764705882355,"d":"4.19"}]
[null,"ExRate EGP/USD (2023)",null,"3.67"]
[null,"Source: World Bank Open Data.",{"$nulls":4},"Cost Effectivness Threshold (CET)"]
[null,"GDP per capita ",null,{"v":194424.856,"d":"AED 194,425"},null,null,{"v":611151.6613235294,"d":"611,152"}]
[]
[null,null,"Costs","QALYs"]
[{"$nulls":11},"Effectiveness"]
[null,"Old Intervention",{"v":200,"d":"200 "},1.5]
[{"$nulls":11},"Cost-Effective"]
[null,"New Intervention",{"v":100,"d":"100 "},2,{"$nulls":3},"WTP",0,0.8,-0.8]
[{"$nulls":8},0,{"v":488921.3290588236,"d":"488,921"},{"v":-488921.3290588236,"d":"(488,921)"},"ICER"]
[{"$nulls":7},"Delta Costs",{"v":-100,"d":"(100)"}]
[null,"Remaining QALYs expectation",{"$nulls":5},"Delta QALYs",0.5,null,null,"Intervention is Dominant"]
[null,"With Disease",null,75,{"$nulls":3},"ICER","Intervention is Dominant"]
[null,"Without Disease",null,85,{"$nulls":7},"NMB"]
[]
[{"$nulls":11},{"v":305675.8306617647,"d":"305,676"}]

{"sheet":"Scenarios","index":2,"n_rows":17,"n_cols":24,"rows_kept":17,"hidden":true,"merged":[[1,11,2,12],[3,11,4,12]],"read":"bin_skipped_in_rows","flags":["formulas_cached_only","records_skipped"],"rows_in_doubt":{"n":4,"rows":[1,2,3,4]},"rows_in_doubt_other":1}
[null,"Costs new","Costs old","QALY new","QALY old","Orphan","IRQG","Multiplier","CET (Public)","CET (private)","ICER",{"$nulls":4},"Manual testing","SMA gene therapy"]
["Vaccination",119.2,85.51,42.989327995912454,42.9873226913501,"No",{"v":4.664656685360086e-05,"d":"0.00"},1,{"v":194424.856,"d":"EGP 194,424.856"},{"v":388849.712,"d":"EGP 388,849.712"},{"v":16800.4405078865,"d":"16,800"},"Non-orphan interventions tested and validated correctly",{"$nulls":6},"Weight"]
["Xospata",119571.41003770372,48929.40433084526,3.120014532636714,1.7909541874943724,"No",{"v":0.4259788956877573,"d":"0.43"},2.5,{"v":486062.14,"d":"EGP 486,062"},{"v":972124.28,"d":"EGP 972,124"},{"v":53151.842175603204,"d":"53,152"},{"$nulls":4},"Severity","Chronic life threatening",{"v":1,"d":"100%"},{"v":0.38640209518664786,"d":"38.6%"},{"v":0.38640209518664786,"d":"38.6%"}]
["SMA gene therapy",{"v":5034806,"d":"$5,034,806"},{"v":923335,"d":"$923,335"},2.574,0.301,"Yes",{"v":0.883061383061383,"d":"0.88"},3,{"v":583274.568,"d":"EGP 583,275"},{"v":1166549.136,"d":"EGP 1,166,549"},{"v":1808830.1803783549,"d":"1,808,830"},"Orphan interventions tested and validated correctly",null,"Wang, T., Scuffham, P., Byrnes, J., & Downes, M. (2022). Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia. Journal of Neurology, 269(12), 6544-6554.",null,"Rarity","Ultra-rare diseases",{"v":1,"d":"100%"},{"v":0.2415013094916549,"d":"24.2%"},{"v":0.2415013094916549,"d":"24.2%"}]
["MM treatment",{"v":823321,"d":"823,321.00"},{"v":733277,"d":"733,277"},5.6,4.3,"Yes",{"v":0.23214285714285712,"d":"0.23"},2,{"v":388849.712,"d":"EGP 388,850"},{"v":777699.424,"d":"EGP 777,699"},{"v":69264.61538461539,"d":"69,265"},null,null,"Blommestein, H. M., Franken, M. G., van Beurden-Tan, C. H., Blijlevens, N. M., Huijgens, P. C., Sonneveld, P., ... & Zweegman, S. (2021). Cost-effectiveness of novel treatment sequences for transplant-ineligible patients with multiple myeloma. JAMA network open, 4(3), e213497-e213497.",null,"Budget Impact","Between 0.01-0.05% of annual drug budget",{"v":0.75,"d":"75%"},{"v":0.16100087299443663,"d":"16.1%"},{"v":0.12075065474582747,"d":"12.1%"}]
[{"$nulls":15},"Credibility","Supportive RCT with at least 1 year follow-up",{"v":0.75,"d":"75%"},{"v":0.10157783785137958,"d":"10.2%"},{"v":0.07618337838853469,"d":"7.6%"}]
[{"$nulls":15},"Age","Pediatrics (0-16 years)",{"v":1,"d":"100%"},{"v":0.06388543261093056,"d":"6.4%"},{"v":0.06388543261093056,"d":"6.4%"}]
[{"$nulls":15},"Societal impact","There is no evidence of societal burden",{"v":0,"d":"0%"},{"v":0.04563245186495041,"d":"4.6%"},{"v":0,"d":"0.0%"}]
[{"$nulls":5},0.1,1,{"$nulls":12},{"v":0.8887228704235955,"d":"89%"},1.777445740847191,2.777445740847191,{"v":1620013.464636085,"d":"EGP 1,620,013.46"},{"v":3240026.92927217,"d":"EGP 3,240,027"}]
[{"$nulls":5},0.25,2,{"$nulls":8},"Manual testing","MM treatment"]
[{"$nulls":5},0.5,2.5,{"$nulls":8},"Severity","Chronic with severe invalidity",{"v":0.6,"d":"60%"},{"v":0.38640209518664786,"d":"38.6%"},{"v":0.23184125711198872,"d":"23.2%"}]
[{"$nulls":5},1,3,{"$nulls":8},"Rarity","Rare diseases",{"v":0.75,"d":"75%"},{"v":0.2415013094916549,"d":"24.2%"},{"v":0.18112598211874117,"d":"18.1%"}]
[{"$nulls":15},"Budget Impact","Below 0.01% of annual drug budget",{"v":1,"d":"100%"},{"v":0.16100087299443663,"d":"16.1%"},{"v":0.16100087299443663,"d":"16.1%"}]
[{"$nulls":15},"Credibility","Supportive RCT and real-world evidence",{"v":1,"d":"100%"},{"v":0.10157783785137958,"d":"10.2%"},{"v":0.10157783785137958,"d":"10.2%"}]
[{"$nulls":15},"Age","Old age adults (above 65 years)",{"v":0,"d":"0%"},{"v":0.06388543261093056,"d":"6.4%"},{"v":0,"d":"0.0%"}]
[{"$nulls":15},"Societal impact","There is evidence on significant societal burden on patients or caregivers",{"v":0.75,"d":"75%"},{"v":0.04563245186495041,"d":"4.6%"},{"v":0.034224338898712806,"d":"3.4%"}]
[{"$nulls":19},{"v":0.709770288975259,"d":"71%"},1.419540577950518,2.419540577950518,{"v":940837.6569083725,"d":"EGP 940,837.66"},{"v":1881675.313816745,"d":"EGP 1,881,675.31"}]

{"sheet":"Calculations","index":3,"n_rows":2,"n_cols":2,"rows_kept":2,"merged":[[0,0,0,2]],"flags":["formulas_cached_only"]}
["Scores"]
["Rare disease factor",1]

{"sheet":"GDPCapita","index":4,"n_rows":15,"n_cols":3,"rows_kept":15,"flags":["formulas_cached_only"]}
["GDPUAE",null,"Recent_year_UAE"]
["52,976.8",null,"2023"]
[]
[]
["World Bank Open Data. (n.d.-b). World Bank Open Data. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=AE"]
[]
[]
[]
[]
[]
[]
["ExRate_UAE",null,"Ex_rate_year"]
["3.67",null,2023]
[]
["World Bank Open Data. (n.d.). World Bank Open Data. https://data.worldbank.org/indicator/PA.NUS.FCRF?locations=AE"]